A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Active, not recruiting · Phase 3 · NCT05827016
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $217,449
- U.S. investigators named
- 23
- Sites paid
- 7
- Planned or actual enrollment
- 1,230
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Iberdomide (drug), Lenalidomide (drug)
- Dates
- Started 2023-06-22; completion 2036-01-01
- Results posted
- Not yet
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
From ClinicalTrials.gov, last updated 2026-09-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $217,449 in research payments for this study in 2025 (32 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John M. Burke, MD Hematology & Oncology · Aurora, CO
- Robert M. Rifkin, MD Hematology & Oncology · Denver, CO
- Ivan M. Borrello, M.D. Medical Oncology · Tampa, FL
- Charles D. Bodine JR., M.D. Hematology & Oncology · Athens, GA
- Amany Keruakous, M.D. Hematology & Oncology · Augusta, GA
- Sagar Lonial, M.D. Hematology · Atlanta, GA
- Muthalagu Ramanathan, MD Hematology & Oncology · Worcester, MA
- Jose L. Mendoza, M.D. Hematology & Oncology · Clinton, MD
- Philip Kuriakose, M.D. Internal Medicine · Detroit, MI
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Andrew L. Sochacki, M.D. Hematology & Oncology · Grand Rapids, MI
- Suman Kambhampati, MD Hematology & Oncology · Kansas City, MO
- John S. Hrom, MD Hematology & Oncology · Hattiesburg, MS
- Raymond Thertulien, M.D. Hematology · Charlotte, NC
- Mohamad A. Cherry, MD Hematology & Oncology · Morristown, NJ
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Gareth Morgan, MD Hematology & Oncology · New York, NY
- Kruti Patel, DO Hematology & Oncology · Cincinnati, OH
- Al-ola A. Abdallah, M.D Internal Medicine · Tulsa, OK
- Christopher A. Yasenchak, M.D. Hematology & Oncology · Eugene, OR
- Adam F. Binder, MD Hematology & Oncology · Philadelphia, PA
- Kathleen A. Dorritie, MD Hematology & Oncology · Pittsburgh, PA
- Houston E. Holmes III, M.D. Hematology & Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rocky Mountain Cancer Centers LLP $75,835
- Maryland Oncology Hematology, PA $50,514
- Advarra $35,830
- Oncology Associates of Oregon, PC $29,185
- Texas Onco Southwest Fort Worth $20,959
- Oncology Hematology Care, Inc $2,805
- NYU Langone Perlmutter Cancer Center $2,321
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.